BILLERICA, Mass., March 12 /PRNewswire/ -- Seahorse Bioscience, Inc., leader in the real-time measurement of cellular bioenergetics, announced today that the XF96 Extracellular Flux Analyzer, the first analytical instrument for the kinetic measure of mitochondrial oxygen consumption and cytoplasmic glycolysis in a 96-well microplate, was selected as the Best New Product for Drug Discovery Assays & Kits by researchers at the Molecular Medicine Tri-Conference in San Francisco.
"The XF96 Analyzer has revolutionized the way we approach toxicity screening," said Yvonne Will of Pfizer's Compound Safety Prediction Group, who spoke about mitochondrial toxicity at the conference and one of the first users of the XF96. "Since getting the high throughput capabilities of the XF96 Analyzer, we routinely generate 6 point cellular bioenergetic EC50's on our drug candidates - something that just wasn't possible before."
XF Analyzers enable researchers to simultaneously measure the two major energy-producing pathways of the cell in real-time, delivering easy-to-use, information-rich bioenergetic assays to study and develop treatments for obesity, diabetes, ageing and cancer, and to screen for mitochondrial toxicity.
The XF96 Analyzer offers the distinct advantage of making it possible to perform these complex bioenergetic assays in a 96-well microplate. XF Analyzers replace Clark-type electrodes, oxygen or pH sensitive dyes, and radiolabeled substrates.
"Prior to the introduction of our XF instruments the standard method for oxygen measurements was using a Clark electrode, invented in 1953, and a flask of millions of cells," stated Steve Chomicz, Seahorse VP Sales & Marketing. "The XF is the new standard and this award mirrors the positive response we experience everyday from researchers struggling to measure cellular bioenergetics. Seahorse and the XF development team are delighted with CHI's recognition of the value of the XF platform."
About Seahorse Bioscience
Seahorse XF instruments have become the new standard in cellular bioenergetic measurements. Scientists worldwide use these tools to advance their research in understanding the role of mitochondrial function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity. Founded in 2001, Seahorse is headquartered in Billerica, MA. For more information, please visit http://www.seahorsebio.com.
CONTACT: Media, Cynthia Egan of Seahorse Bioscience, Inc., +1-978-671-1610
Web site: http://www.seahorsebio.com/
